Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.
about
Novel strategies to target the ubiquitin proteasome system in multiple myelomaFrom clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myelomaNeuropathic cancer pain: What we are dealing with? How to manage it?Omuralide and vibralactone: differences in the proteasome- β-lactone-γ-lactam binding scaffold alter target preferencesAAPT Diagnostic Criteria for Chronic Cancer Pain ConditionsBortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouseIntegrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibBortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsIdentification of agents that promote endoplasmic reticulum stress using an assay that monitors luciferase secretion.The 26S proteasome complex: an attractive target for cancer therapyUpdate on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomibUse of antineoplastic agents in patients with cancer who have HIV/AIDS.A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats.Bortezomib for the treatment of non-Hodgkin's lymphomaSubclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy.Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphomaBortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence.Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.Pain in malignant hematology.Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique.Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma.Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy.MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinicCarfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry.Surgical Roles for Spinal Involvement of Hematological Malignancies.Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity.Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study.Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy
P2860
Q26773246-A594A161-EF69-45FF-8730-DB70EFFA491FQ26862828-4FC2A60B-40A8-41DC-87ED-43B4BC570193Q26998945-74EE2F93-4CD3-4794-94C2-383D73A70052Q27687714-C6DB8657-A84E-4C95-BF84-1E19C88319A8Q28079708-66C11027-14B2-43AE-895A-5B7C39134029Q28533426-491CC5EB-C71C-4409-8BF4-D375A5DBA02FQ33409681-34D45558-9A75-4BD7-819D-933F0337194BQ33425190-44128268-5D60-48F7-80DC-9C6C6E052272Q33617012-C90B73C5-8EB2-4D9E-8E62-2877FE689338Q34218976-13D5379C-89C5-479E-826A-3A266F6EDCDEQ35076504-294DB792-7DC5-4DA0-9EF5-DBBE9DE2AA00Q35624079-1236AC58-EFFB-4A6F-A2CC-A16222596FEEQ35905929-F295C537-7048-45BA-997B-FA2B6C38E986Q35932561-8FE515A5-1AAC-4165-AFB3-56AD1B2BA2E3Q36037229-2FA15D9C-E6CD-4499-BB46-7E3A146B97BDQ36084704-FCBF5600-46AB-4167-9456-3F4763166041Q36868056-4FF3433E-3426-42FD-BC2F-C559F29B08DFQ36893299-0BB59370-4035-47EF-86EE-BCF5B161B472Q36893329-E97BA084-ED31-4088-AF74-7BF8982AEBD1Q37140809-FC039351-2AB2-4093-A145-5CBBD8B65CEBQ37146294-881AEF59-DA6E-4282-B252-C37BCF014520Q37659699-1C3D597C-B647-4998-80E8-8718F1B21C58Q37662576-2E4004E5-C103-4F80-A18D-A10C345BF0E9Q37842353-37271FAE-55E0-4916-B7EB-472D5603CCFAQ37923308-0EA874C8-A409-4F79-9F9D-90E4D2554283Q38019864-DADC56A8-77CC-4FE3-B6E9-D17C2C72C899Q38044986-16BBCF4F-4416-4B03-BB2F-C8E797F983E8Q38068534-88C80067-5C85-43B9-90E6-EC06B3303E55Q38738098-5A57B033-8555-4703-A3EC-4EDBA61ECB03Q38986185-AFA36C4B-FF29-4A3D-A553-3675DFD6A4F6Q39043749-27B82843-3981-45F8-A82E-37BC8DA8B64AQ39101546-6259C8E7-FAA0-4260-90ED-A223DA89B1C8Q39289240-F9A76A89-640E-4713-9E51-4135BA194815Q39298317-7131B2E4-7E31-47FA-8719-D8989729EF41Q39569161-A68D861D-130A-456D-8C80-C95A4FD54D69Q39591636-9AB26941-12E2-4915-9431-9D5A9F59D951Q40053632-3131AE8B-6BF1-4223-84CE-9327D28A8E76Q40621650-BD94C6E2-E2E2-4EEF-821E-67CC7D6DD8A8Q41705410-40D31F94-FA0E-4EBC-A78B-F6A58D18D994Q41943563-4A304374-E6D2-4C93-A571-7DF13D461A36
P2860
Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Peripheral neuropathy during b ...... a: a review of recent studies.
@en
Peripheral neuropathy during b ...... a: a review of recent studies.
@nl
type
label
Peripheral neuropathy during b ...... a: a review of recent studies.
@en
Peripheral neuropathy during b ...... a: a review of recent studies.
@nl
prefLabel
Peripheral neuropathy during b ...... a: a review of recent studies.
@en
Peripheral neuropathy during b ...... a: a review of recent studies.
@nl
P2860
P1433
P1476
Peripheral neuropathy during b ...... a: a review of recent studies.
@en
P2093
Andrzej J Jakubowiak
P2860
P304
P356
10.3109/10428194.2010.483303
P577
2010-07-01T00:00:00Z